Skip to main content
Preventing Severe RSV Disease in Infants
Respiratory syncytial virus (RSV) is a leading cause of hospitalization among infants, and current RSV immunization recommendations can be complex for healthcare providers and practice teams to implement. This module reviews the importance of infant RSV prevention, including maternal RSV vaccination and preventive monoclonal antibodies for infants and young children. Learners will explore common recommendation and administration challenges, identify technical errors to avoid, and review practical resources that can help answer questions from both clinicians and parents.
Authored by Sharon Humiston, MD, MPH, FAAP, in collaboration with IKC.
Accreditation
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by PRIME Education (PRIME®) and Immunize Kansas Coalition. PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation Statement
PRIME® designates this Enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Associate Accreditation Statement
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until 7/1/2029. PAs should only claim credit commensurate with the extent of their participation.
Pharmacist Accreditation Statement
This Knowledge-based activity has been approved for 0.5 contact hour (0.1 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-9999-26-372-H06-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service ([email protected]).
Nurse Credit Designation Statement
PRIME® designates this activity for 0.5 contact hour.
Credit Center
To receive credit, please visit https://primeinc.org/evaluation/75PR263.
PRIME® Policies
Mitigating Conflicts of Interest
PRIME Education, LLC (PRIME®) adheres to the ACCME's Standards of Integrity and Independence in Accredited Continuing Education, in compliance with Joint Accreditation. These Standards require everyone in a position of controlling the content of a CE activity to disclose all financial relationships with ineligible companies. CE activities must offer fair and balanced content, remain independent of commercial bias, and be designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest arises when individuals in a position of controlling the content of CE activities have a relevant financial relationship with an ineligible company that may bias their opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
PRIME® has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Unapproved Uses
Presentations may provide information in whole or in part related to non-FDA-approved uses of drugs and/or devices or may discuss the unlabeled indications or the investigational nature of their proposed uses. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
Disclaimer
The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, Joint Accreditation (ACCME, AAPA, ACPE, ANCC, ARBO COPE, APA, ADA), AAPA or other relevant accreditation bodies. Questions? Please email [email protected].
Disclosures
There is no commercial or in-kind support for this activity.
*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.
The following individuals have identified relevant financial relationships with ineligible companies to disclose:
- Sharon Humiston, MD, MPH (Course Director, Contributing Author)
Speakers Bureau or other Promotional Education – Merck Vaccine Division, Sanofi Pasteur - The relationships reported above are related to the following therapeutic area: Vaccines
- Kristi Kay Orbaugh, RN, MSN, RNP, AOCN (Planner)
Speakers Bureau or other Promotional Education – AstraZeneca, Bristol-Myers Squibb, DSI, Exilixis, Gilead Sciences, Pfizer, Stemline - The relationships reported above are related to the following therapeutic area: Oncology
The following individuals have no relevant financial relationships with ineligible companies to disclose:
- Annette Sophin, MSMM, PA-C (Reviewer)
- Abimbola Farinde, PhD, PharmD (Planner)
- All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.